Precision Peptide Company Inc · CSE:BPC
Precision Peptide — The Precision Peptide Company — Investor Presentation (August 2026)
21 slides from Precision Peptide's investor presentation, August 2026
Slide 1: The Precision Peptide Company: Peptides, reimagined
The Precision Peptide Company INVESTOR PRESENTATION - AUGUST 2026 Peptides, reimagined. Engineering the next generation of human performance — clinical-grade peptides, delivered without needles. he goSe BPC . OTCQB PNGAF
Slide 2: $157B, 25M, $6.8T market figures
$157B 25M $6.8T Projected global GLP-1 market by 2030 — Americans forecast to be on GLP-1 therapy Global wellness economy in 2024, forecast up from $53.5B in 2024. Ozempic and by 2030 — 2.5× today. A generation is being to reach $9.8T by 2029. Optimization Wegovy made "peptide" a household word. tra
Slide 3: Most peptides still require syringes
Most peptides still require syringes — a hard stop for Refrigeration, reconstitution and mixing make Compounding channels leave consumers uncertain the mainstream consumer. distribution costly and fragile. about quality, sourcing and compliance.
Slide 4: Single-use patches per pack
A S F E AT U R E D I N 10 single-use patches per pack Pre-measured dose No cold storage US-made · LegitScript-certi�ed
Slide 5: A temperature-stable matrix preserves peptide integrity
1 A temperature-stable matrix preserves peptide integrity — no refrigeration, no reconstitution, no waste. 2 Absorption enhancers carry the compound through the stratum corneum — the skin barrier that defeats ordinary topicals. 3 Micro-dosed delivery over the wear period, designed for steadier avail
Slide 6: Precisely dosed, pre-measured delivery
≥ Precisely dosed, pre-measured Made in approved United States Traceable, compliant formulations — delivery. facilities. quality a consumer can verify. Chromatographic purity (95.5%) and content (2.02 mg per patch) per independent third-party laboratory analysis of the BPC-157 Recovery Patch, as rep
Slide 7: On the market today
On the market today — US-made, third- party tested, LegitScript-certi�ed. Cellular energy & vitality† Focus & memory† Recovery & gut health† Relaxation & sleep† Gut balance & recovery† Scalp & follicle support† †Label structure/function statements. These statements have not been evaluated by the Foo
Slide 8: Recovery Patch, TA-1 Immunity Patch, GLP-1 Patch
The Recovery Patch TA-1 Immunity GLP-1 Patch Patch 20,000−unit production run received July 2026. Featured in Men's Health. 95.5% A needle-free tirzepatide format pointed at A �rst-to-market immune-support patch — the US$62–66B global GLP-1 market — a purity independently veri�ed. Thymosin Alpha-1 i
Slide 9: Telehealth & pharmacy fulfillment
telehealth & pharmacy ful�llment up to ~25,000 prescriptions/day capacity R X O N LY R X O N LY R X O N LY Prescription products dispensed only pursuant to a valid prescription following consultation with a licensed independent compliance seal announced August 2026 — see FLS provider.
Slide 10: Every prescription product is prescribed by a licensed provider
Every prescription product is prescribed by a licensed provider through the Company's nationwide telehealth platform and compounded 100% in the United States — a pharmacy supply chain patients and investors can verify. LegitScript-certi�ed · 503A-regulated US compounding 1 Licensed-provider consulta
Slide 11: U.S. regulators are moving against grey-zone compounded peptides
U.S. regulators are moving against grey- Consumers moved from reactive treatment No trusted consumer brand yet owns zone compounded peptides — rewarding to proactive optimization — and expect needle-free peptide delivery. That is the companies built compliant from day one. consumer-grade convenience
Slide 12: TPPC operates where three vast markets overlap
The cultural tide $6.8T TPPC operates where three vast markets overlap: The retail channel $209B validated peptide science, the supplement economy, and the global wellness movement — selling consumer formats of a molecule class supported by a growing $140B+ body of clinical evidence. Sources: Global
Slide 13: Direct-to-consumer, subscription, omnichannel, B2B licensing
Direct-to-consumer Subscription Omnichannel B2B licensing High-margin sales on our own 30−day patch supplies create Retail and partner distribution — Future licensing of the proprietary platform — all customers now natural replenishment cycles and anchored by the MMA.INC delivery matrix to pharma an
Slide 14: MMA.INC strategic marketing agreement
Co-founder · Conor Non- Strategic Strategic McGregor's coach executive investor investor director 5M+ 530K 18,000 75/25 social followers user pro�les gyms on platform · 800+ revenue share to TPPC veri�ed from year two strategic marketing active students US-made · agreement · signed May 8, 2026 train
Slide 15: Recent milestones and developments
— access to a global combat-sports audience across 22 countries. — third-party lab con�rms the BPC-157 patch clears the ≥95% industry benchmark. — seven products in stock, all 50 states; four of the backed peptides already in TPPC formulations. — Amino Innovations store and customers migrated to pre
Slide 16: The playbook: Hims & Hers and Ro
16× REVENUE GROWTH IN F IV E Y EA RS → The playbook: four months apart — both sold ~$6.7B market cap · 2.5M+ subscribers · revenue per public �lings through telehealth from $149/mo. The data is clear: the delivery method, not the molecule, is what unlocks the broader market. — the next wave queuing
Slide 17: Comparable market values and TPPC positioning
circle area = market value High-margin DTC + subscription Nationwide telehealth Rx GLP-1 access $6.7B ~$7B Patch purity, independently veri�ed CSE: BPC · C$0.45 NYSE: HIMS last round · Feb 2022 Exclusive MMA.INC audience Patch production run · July 2026 National press ~C$24M market cap at C$0.45 · ~
Slide 18: Management and board
PS JK MS Public-company CEO leading TPPC's strategy 30+ years in drug development and delivery- Built and scaled culture-de�ning consumer and capital markets presence; trained in system innovation; patent holder and architect of media at High Times; brand and audience marketing & sales (BCIT) and ex
Slide 19: Capital structure and contact
TPPC C A P I TA L S T R U C T U R E · A S AT AU G U S T 2 0 2 6 Issued & outstanding Warrants Options C A N A DA U N I T E D S TAT E S Share price · market cap CSE: BPC OTCQB: PNGAF pratap@precisionpeptidecompany.com precisionpeptidecompany.com Forward-looking statements: Certain statements in this
Slide 20: This presentation has been prepared by The Precision Peptide Company
1/2 This presentation has been prepared by “forward-looking statements” and “forward-looking information” wellness markets, and the Company’s positioning within them; the The Precision Peptide Company (the “Company” or “Precision within the meaning of applicable Canadian securities legislation Compa
Slide 21: Forward-looking statements are not guarantees of future performance
2/2 Forward-looking statements are not to raise capital; and other risk factors described in the Company’s Company’s continuous disclosure documents �led under the guarantees of future performance. They involve known and unknown public �lings available on SEDAR+ at www.sedarplus.ca. Company’s pro�le
The Precision Peptide Company — Investor Presentation (August 2026) on 6ix